Despite significant advances in the treatment and prognosis of colorectal cancer (CRC), not all tumors respond to current treatment modalities and patients with advanced disease continue to have a poor prognosis. New treatment strategies are needed to improve long-term survival in colorectal cancer patients with metastatic disease. Adoptive cell therapy is a novel approach that uses one’s own immune cells to target tumor cells directly. For the last two decades, a wide variety of methods have been described. T-lymphocyte-based immunotherapy may be a promising alternative treatment capable of mediating durable regressions in patients with advanced colorectal cancer.